Cytokinetics, Inc. (CYTK)
72.72
-1.23
(-1.66%)
USD |
NASDAQ |
Sep 04, 16:00
72.70
-0.02
(-0.03%)
Pre-Market: 20:00
Cytokinetics Research and Development Expense (Quarterly) : 94.18M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 94.18M |
| March 31, 2026 | 92.15M |
| December 31, 2025 | 101.54M |
| September 30, 2025 | 96.55M |
| June 30, 2025 | 110.27M |
| March 31, 2025 | 97.54M |
| December 31, 2024 | 91.25M |
| September 30, 2024 | 82.20M |
| June 30, 2024 | 77.19M |
| March 31, 2024 | 79.24M |
| December 31, 2023 | 78.64M |
| September 30, 2023 | 80.68M |
| June 30, 2023 | 80.40M |
| March 31, 2023 | 76.64M |
| December 31, 2022 | 72.28M |
| September 30, 2022 | 60.65M |
| June 30, 2022 | 55.12M |
| March 31, 2022 | 44.37M |
| December 31, 2021 | 40.81M |
| September 30, 2021 | 42.57M |
| June 30, 2021 | 35.90M |
| March 31, 2021 | 31.02M |
| December 31, 2020 | 28.75M |
| September 30, 2020 | 23.67M |
| June 30, 2020 | 21.37M |
| Date | Value |
|---|---|
| March 31, 2020 | 21.33M |
| December 31, 2019 | 17.94M |
| September 30, 2019 | 20.23M |
| June 30, 2019 | 24.02M |
| March 31, 2019 | 23.54M |
| December 31, 2018 | 23.28M |
| September 30, 2018 | 21.39M |
| June 30, 2018 | 21.58M |
| March 31, 2018 | 22.14M |
| December 31, 2017 | 26.25M |
| September 30, 2017 | 24.95M |
| June 30, 2017 | 19.81M |
| March 31, 2017 | 19.29M |
| December 31, 2016 | 18.78M |
| September 30, 2016 | 17.86M |
| June 30, 2016 | 14.22M |
| March 31, 2016 | 13.53M |
| December 31, 2015 | 13.25M |
| September 30, 2015 | 11.56M |
| June 30, 2015 | 12.64M |
| March 31, 2015 | 8.956M |
| December 31, 2014 | 8.779M |
| September 30, 2014 | 11.42M |
| June 30, 2014 | 11.74M |
| March 31, 2014 | 12.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | 2.316B |
| Krystal Biotech, Inc. | 13.16M |
| Ionis Pharmaceuticals, Inc. | 216.41M |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |